Pulmonary arterial hypertension: challenges and achievements 2021

Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment go...

Full description

Saved in:
Bibliographic Details
Main Authors: E. A. Rezukhina, T. V. Martynyuk, Z. S. Valieva, V. V. Gramovich, I. E. Chazova
Format: Article
Language:Russian
Published: InterMedservice 2022-03-01
Series:Евразийский Кардиологический Журнал
Subjects:
Online Access:https://www.heartj.asia/jour/article/view/6304
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment goals achievement, COVID-19 pandemic challenges impact on routine clinical practice is demonstrated. In this review current situation in pulmonary arterial hypertension treatment goals and regular risk stratification importance are observed, based on the latest clinical trials combined specific therapy including selective prostacyclin receptor agonist selexipag is demonstrated. special attention is paid to pulmonary hypertension patients’ treatment during COVID-19 pandemic, regular risk stratification necessity is mentioned including remote patient monitoring in order to perform timely escalation in PAH-specific treatment in order to achieve low-risk status and to improve the prognosis of PAH patients.
ISSN:2225-1685
2305-0748